Effects of 18-month Vildagliptin Treatment on Portal Vein Pressure and Hepatosteatosis

Karatoprak C. , Kilicarslan R., Çakırca M. , Aydin S., Ozkan T., Zorlu M. , et al.

BEZMIALEM SCIENCE, cilt.7, ss.317-321, 2019 (ESCI İndekslerine Giren Dergi)


Objective: Patients with type 2 diabetes have an increased tendency to develop hepatosteatosis. The effects of drugs used to treat diabetes on the liver, regardless of the disease, are unknown.The aim of this study was to investigate the effects of vildagliptin, a dipeptidyl peptidase-4 inhibitor, on the portal vein pressure and hepatosteatosis in patients with type 2 diabetes in the 18 months of follow-up.